MCID: OVR123
MIFTS: 39

Ovarian Seromucinous Carcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovarian Seromucinous Carcinoma

MalaCards integrated aliases for Ovarian Seromucinous Carcinoma:

Name: Ovarian Seromucinous Carcinoma 12 15
Mixed Epithelial Carcinoma of Ovary 12
Ovary Mixed Epithelial Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6898
NCIt 51 C40090
UMLS 74 C0279392

Summaries for Ovarian Seromucinous Carcinoma

Disease Ontology : 12 An ovarian carcinoma that is biphasic and has material basis in epithelial and mesenchymal elements.

MalaCards based summary : Ovarian Seromucinous Carcinoma, also known as mixed epithelial carcinoma of ovary, is related to colonic disease and cellular schwannoma. An important gene associated with Ovarian Seromucinous Carcinoma is CDX2 (Caudal Type Homeobox 2), and among its related pathways/superpathways are Gastric cancer and Cell cycle Role of SCF complex in cell cycle regulation. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, liver and brain, and related phenotypes are cellular and cardiovascular system

Related Diseases for Ovarian Seromucinous Carcinoma

Diseases related to Ovarian Seromucinous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 colonic disease 10.3 CDX2 ESR1
2 cellular schwannoma 10.2 CDKN2A PAX8
3 leiomyoma, uterine 10.2 ESR1 PGR
4 adenomyosis 10.2 ESR1 PGR
5 female breast cancer 10.2 ESR1 PGR
6 reproductive organ benign neoplasm 10.2 ESR1 PGR
7 ductal carcinoma in situ 10.2 ESR1 PGR
8 estrogen-receptor positive breast cancer 10.2 ESR1 PGR
9 estrogen-receptor negative breast cancer 10.2 ESR1 PGR
10 endometritis 10.2 ESR1 PGR
11 prostatic hypertrophy 10.2 ESR1 PGR
12 gynecomastia 10.2 ESR1 PGR
13 breast fibroadenoma 10.2 ESR1 PGR
14 fallopian tube carcinoma 10.2 ESR1 PGR
15 angiomyolipoma 10.2 ESR1 PGR
16 sporadic breast cancer 10.2 ESR1 PGR
17 breast carcinoma in situ 10.2 ESR1 PGR
18 juvenile nasopharyngeal angiofibroma 10.2 ESR1 PGR
19 colorectal adenocarcinoma 10.2 CDX2 KRT7
20 ampulla of vater cancer 10.2 CDX2 KRT7
21 small intestine cancer 10.2 CDX2 KRT7
22 cecum adenocarcinoma 10.2 CDX2 KRT7
23 pseudomyxoma peritonei 10.2 CDX2 KRT7
24 gastric signet ring cell adenocarcinoma 10.2 CDX2 PGR
25 bronchiolo-alveolar adenocarcinoma 10.2 CDX2 KRT7
26 leiomyomatosis 10.2 ESR1 PGR
27 gastric tubular adenocarcinoma 10.2 CDX2 KRT7
28 myoma 10.2 ESR1 PGR
29 cystitis cystica 10.2 CDX2 KRT7
30 intestinal obstruction 10.2 CDX2 KRT7
31 vestibular gland benign neoplasm 10.2 ESR1 PGR
32 bartholin's gland adenoma 10.2 ESR1 PGR
33 vulvar syringoma 10.2 ESR1 PGR
34 lung leiomyoma 10.2 ESR1 PGR
35 glassy cell carcinoma of the cervix 10.2 ESR1 PGR
36 thymus cancer 10.2 KRT7 PAX8
37 vulvar benign neoplasm 10.2 ESR1 PGR
38 trigonitis 10.2 ESR1 PGR
39 vulvar leiomyoma 10.2 ESR1 PGR
40 vulvar dystrophy 10.2 CDKN2A PGR
41 predominantly cortical thymoma 10.2 ESR1 PGR
42 ovary neuroendocrine neoplasm 10.2 CDX2 KRT7
43 breast medullary carcinoma 10.2 ESR1 PGR
44 breast scirrhous carcinoma 10.2 ESR1 PGR
45 bizarre leiomyoma 10.2 CDKN2A PGR
46 progesterone-receptor positive breast cancer 10.2 ESR1 PGR
47 progesterone resistance 10.2 ESR1 PGR
48 appendix adenocarcinoma 10.2 CDX2 KRT7
49 anus adenocarcinoma 10.2 CDX2 KRT7
50 apocrine adenocarcinoma 10.2 ESR1 PGR

Graphical network of the top 20 diseases related to Ovarian Seromucinous Carcinoma:



Diseases related to Ovarian Seromucinous Carcinoma

Symptoms & Phenotypes for Ovarian Seromucinous Carcinoma

MGI Mouse Phenotypes related to Ovarian Seromucinous Carcinoma:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.02 CDKN2A CDX2 ESR1 KRT7 PAX8 PGR
2 cardiovascular system MP:0005385 9.97 CDKN2A CDX2 ESR1 PAX8 PGR WT1
3 homeostasis/metabolism MP:0005376 9.95 CDKN2A CDX2 ESR1 KRT7 PAX8 PGR
4 embryo MP:0005380 9.93 CDKN2A CDX2 ESR1 PAX8 PGR WT1
5 endocrine/exocrine gland MP:0005379 9.91 CDKN2A CDX2 ESR1 PAX8 PGR WT1
6 neoplasm MP:0002006 9.72 CDKN2A CDX2 ESR1 PGR WT1
7 limbs/digits/tail MP:0005371 9.67 CDX2 ESR1 PAX8 PGR
8 no phenotypic analysis MP:0003012 9.65 CDKN2A ESR1 PAX8 PGR WT1
9 normal MP:0002873 9.55 CDX2 ESR1 PAX8 PGR WT1
10 reproductive system MP:0005389 9.43 CDKN2A CDX2 ESR1 PAX8 PGR WT1
11 skeleton MP:0005390 9.02 CDKN2A CDX2 ESR1 PAX8 PGR

Drugs & Therapeutics for Ovarian Seromucinous Carcinoma

Drugs for Ovarian Seromucinous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
3
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 23214-92-8 31703
4
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
5
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
6
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 1 123948-87-8, 119413-54-6 60700
7
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
9
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
10
Gemcitabine Approved Phase 2, Phase 3,Phase 3 95058-81-4 60750
11
Olaparib Approved Phase 2, Phase 3,Phase 3 763113-22-0 23725625
12
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
13
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 59-30-3 6037
15
Doxil Approved June 1999 Phase 2, Phase 3,Phase 3,Phase 1 31703
16 Paclitaxel poliglumex Experimental, Investigational Phase 3,Phase 1 263351-82-2
17
Cediranib Investigational Phase 2, Phase 3,Phase 3 288383-20-0 9933475
18
SB-649868 Experimental, Investigational Phase 2, Phase 3,Phase 3 110-16-7, 110-17-8 444972
19 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
20 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
21 Antimitotic Agents Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
23 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3,Phase 1
24 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3,Phase 1
25 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
26 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 3,Phase 2
28 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
29 Immunoglobulins Phase 3,Phase 2,Phase 1
30 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
31 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
33 Immunoglobulin G Phase 3,Phase 2,Phase 1
34 Antibodies Phase 3,Phase 2,Phase 1
35 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
36 Mitogens Phase 3,Phase 2,Phase 1
37 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
38 topoisomerase I inhibitors Phase 2, Phase 3,Phase 1
39 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
40 Antirheumatic Agents Phase 3,Phase 2,Phase 1
41 Alkylating Agents Phase 3,Phase 2,Phase 1
42 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
43 Trace Elements Phase 3,Not Applicable
44 Micronutrients Phase 3,Not Applicable
45 Carotenoids Phase 3
46 Antimetabolites, Antineoplastic Phase 3,Phase 2
47 Antimetabolites Phase 3,Phase 2
48 Antiviral Agents Phase 3,Phase 2
49 taxane Phase 3
50 Analgesics Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
3 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
4 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
5 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
7 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
8 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
9 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
10 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
11 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
12 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
13 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
14 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
15 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
16 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
17 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
18 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Unknown status NCT02283658 Phase 2 Everolimus;Letrozole
19 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
20 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
21 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
22 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
23 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
24 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
25 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
26 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
27 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers Completed NCT00002538 Phase 2
28 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
29 MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
30 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
31 Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02923739 Phase 2 Paclitaxel
32 Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2 metformin hydrochloride;placebo;Chemotherapy
33 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
34 First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Active, not recruiting NCT01097746 Phase 2 Carboplatin;Paclitaxel
35 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
36 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer Terminated NCT00004221 Phase 2 Carboplatin;Cyclophosphamide;Paclitaxel;Topotecan Hydrochloride
37 Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
38 EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01489371 Phase 1 Pegylated Liposomal Doxorubicin Hydrochloride
39 Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT01459380 Phase 1 Carboplatin;Pegylated Liposomal Doxorubicin Hydrochloride;Veliparib
40 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
41 TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
42 Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Completed NCT00060359 Phase 1 Carboplatin;Paclitaxel Poliglumex
43 Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00814086 Phase 1 Paclitaxel;Cisplatin
44 Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer Completed NCT00002913 Phase 1 paclitaxel;cisplatin;topotecan hydrochloride
45 Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00079430 Phase 1 paclitaxel;carboplatin
46 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
47 Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00006235 Phase 1 carboplatin;pegylated liposomal doxorubicin hydrochloride
48 Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer Completed NCT00002600 Phase 1 carboplatin;cyclophosphamide
49 Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003967 Phase 1 etoposide;topotecan hydrochloride
50 Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed NCT00408590 Phase 1

Search NIH Clinical Center for Ovarian Seromucinous Carcinoma

Genetic Tests for Ovarian Seromucinous Carcinoma

Anatomical Context for Ovarian Seromucinous Carcinoma

MalaCards organs/tissues related to Ovarian Seromucinous Carcinoma:

42
Ovary, Liver, Brain, Bone, Endothelial, Bone Marrow

Publications for Ovarian Seromucinous Carcinoma

Articles related to Ovarian Seromucinous Carcinoma:

# Title Authors Year
1
Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm. ( 25723110 )
2015

Variations for Ovarian Seromucinous Carcinoma

Expression for Ovarian Seromucinous Carcinoma

Search GEO for disease gene expression data for Ovarian Seromucinous Carcinoma.

Pathways for Ovarian Seromucinous Carcinoma

Pathways related to Ovarian Seromucinous Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.59 CDKN2A CDX2 ESR1 PGR
2
Show member pathways
11.38 CDKN2A ESR1 PGR
3 10.98 ESR1 WT1

GO Terms for Ovarian Seromucinous Carcinoma

Cellular components related to Ovarian Seromucinous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.5 CDKN2A CDX2 ESR1 KRT7 PAX8 PGR
2 nucleoplasm GO:0005654 9.1 CDKN2A CDX2 ESR1 PAX8 PGR WT1

Biological processes related to Ovarian Seromucinous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 9.8 CDX2 ESR1 PAX8 PGR WT1
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.72 CDKN2A ESR1 PAX8 PGR WT1
3 steroid hormone mediated signaling pathway GO:0043401 9.48 ESR1 PGR
4 branching involved in ureteric bud morphogenesis GO:0001658 9.46 PAX8 WT1
5 transcription, DNA-templated GO:0006351 9.43 ESR1 PAX8
6 transcription by RNA polymerase II GO:0006366 9.37 CDX2 ESR1
7 cellular response to gonadotropin stimulus GO:0071371 9.26 PAX8 WT1
8 metanephric epithelium development GO:0072207 9.16 PAX8 WT1
9 positive regulation of transcription, DNA-templated GO:0045893 9.02 CDKN2A CDX2 ESR1 PAX8 WT1
10 metanephric S-shaped body morphogenesis GO:0072284 8.96 PAX8 WT1

Molecular functions related to Ovarian Seromucinous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.65 CDX2 ESR1 PAX8 PGR WT1
2 DNA binding GO:0003677 9.63 CDKN2A CDX2 ESR1 PAX8 PGR WT1
3 steroid hormone receptor activity GO:0003707 9.4 ESR1 PGR
4 nuclear receptor activity GO:0004879 9.37 ESR1 PGR
5 DNA-binding transcription factor activity GO:0003700 9.35 CDX2 ESR1 PAX8 PGR WT1
6 steroid binding GO:0005496 9.32 ESR1 PGR
7 sequence-specific DNA binding GO:0043565 9.02 CDX2 ESR1 PAX8 PGR WT1

Sources for Ovarian Seromucinous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....